St. Jude Medical (STJ) Meets Stopping Rule in RESPECT Trial, Closes Patient Enrollment
Tweet
Share
E-mailGet Alerts STJ Hot Sheet
Join SI Premium – FREE
St. Jude Medical, Inc. (NYSE: STJ), has met a stopping rule in its RESPECT clinical trial – triggered by reaching the protocol-required number of primary events in the trial, defined as stroke and all-cause mortality – and is closing patient enrollment.
The RESPECT trial is a randomized, multi-center study investigating whether closure of the Patent Foramen Ovale (PFO), a congenital heart defect, using the St. Jude Medical AMPLATZER® PFO Occluder device, is safe and effective compared to current standard-of-care treatment in the prevention of a cryptogenic stroke. A cryptogenic stroke is one for which the origin or cause of stroke is unknown.
The RESPECT trial is a randomized, multi-center study investigating whether closure of the Patent Foramen Ovale (PFO), a congenital heart defect, using the St. Jude Medical AMPLATZER® PFO Occluder device, is safe and effective compared to current standard-of-care treatment in the prevention of a cryptogenic stroke. A cryptogenic stroke is one for which the origin or cause of stroke is unknown.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- Real and RE/MAX Holdings set Aug. 24 merger closing date
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
